Incyte Corporation vs Clear Secure Inc — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Clear Secure Inc trades at $42.77 (market cap $4.44B). The key difference: Incyte Corporation is far larger — about 5.1× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.33% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Clear Secure Inc for 19 Days on average.
| INCY | YOU | |
|---|---|---|
Market Cap | $22.85B | $4.44B |
Volume | 1,927,029 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $129.93 | $62.36 |
52-Week Low | $83.80 | $29.61 |
Typical Hold Time | 33 Days | 19 Days |
Enterprise Value | $18.35B | $3.59B |
Dividend Yield | — | 1.33% |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Clear Secure (YOU) trades at $43.43, up 2.0% today, with a bullish technical signal despite overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates with $0.49 versus $0.40 expected, and revenue growth accelerated to 27% year-over-year. Analyst consensus is mixed with a $61.40 price target, and the stock shows robust profitability with a 90.29% ROE and expanding margins.
The outlook is positive given membership growth and new enterprise initiatives, but risks include high valuation multiples and insider selling. The stock offers growth potential driven by identity platform expansion, though investors should weigh competitive pressures and execution risks against strong fundamental trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →